MIR Trial: Rituximab and Radiation for Follicular Lymphoma
Author Information
Author(s): Mathias Witzens-Harig, Manfred Hensel, Michael Unterhalt, Klaus Herfarth
Primary Institution: University of Heidelberg
Hypothesis
The combination of Rituximab and involved field radiation will improve progression-free survival in patients with early stage follicular lymphoma.
Conclusion
The MIR trial aims to evaluate the efficacy and safety of combining Rituximab with involved field radiotherapy for treating early stage follicular lymphoma.
Supporting Evidence
- The trial is designed to test the efficacy and safety of Rituximab combined with radiation therapy.
- The primary endpoint is progression-free survival over two years.
- The study includes 85 patients to evaluate the treatment's effectiveness.
Takeaway
This study is testing if a medicine called Rituximab, when used with radiation, can help people with a type of cancer called follicular lymphoma live longer without the cancer coming back.
Methodology
The study is a prospective multicenter Phase II trial combining Rituximab with involved field radiotherapy in patients with early stage follicular lymphoma.
Limitations
The study may have limitations related to patient selection and the generalizability of results due to its multicenter design.
Participant Demographics
Patients aged 18 to 75 with pathologically documented follicular lymphoma grade 1 or 2 in Ann Arbor Stage I or II.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website